Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Eribulin Mesylate|DRUG: Lobaplatin
Sponsor: Chinese Academy of Medical Sciences